Conatus Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
30.17 M |
Public Float |
28.59 M |
Conatus Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.57 |
Market Cap |
$10.18 M |
Shares Outstanding |
33.17 M |
Public Float |
26.16 M |
Address |
16745 West Bernardo Drive San Diego California 92127 United States |
Employees | - |
Website | http://www.conatuspharma.com |
Updated | 07/08/2019 |
Conatus Pharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of liver diseases. It focuses in development of emricasan, an active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P. |